United Therapeutics (FRA:UTH) 3-Year Book Growth Rate : 18.60% (As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is United Therapeutics 3-Year Book Growth Rate?

United Therapeutics's Book Value per Share for the quarter that ended in Dec. 2023 was €116.67.

During the past 12 months, United Therapeutics's average Book Value per Share Growth Rate was 22.10% per year. During the past 3 years, the average Book Value per Share Growth Rate was 18.60% per year. During the past 5 years, the average Book Value per Share Growth Rate was 15.60% per year. During the past 10 years, the average Book Value per Share Growth Rate was 17.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of United Therapeutics was 106.90% per year. The lowest was -11.80% per year. And the median was 18.00% per year.

Competitive Comparison of United Therapeutics's 3-Year Book Growth Rate

For the Biotechnology subindustry, United Therapeutics's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

United Therapeutics's 3-Year Book Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, United Therapeutics's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where United Therapeutics's 3-Year Book Growth Rate falls into.

United Therapeutics 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

United Therapeutics (FRA:UTH) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

United Therapeutics 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of United Therapeutics's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

United Therapeutics (FRA:UTH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » United Therapeutics Corp (FRA:UTH) » Definitions » 3-Year Book Growth Rate

Comparable Companies

Traded in Other Exchanges

UTHR:USA UTH:Germany

Address

1040 Spring Street, Silver Spring, MD, USA, 20910

Website

https://www.unither.com

United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.

United Therapeutics (FRA:UTH) Headlines

No Headlines